2025
Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial.
Kumar S, Faber E, Cohen A, Callander N, Singh A, Parker T, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Aaron R, Zonder J, Anderson K, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar S, Jacobus S. Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial. Journal Of Clinical Oncology 2025, 43: 7540-7540. DOI: 10.1200/jco.2025.43.16_suppl.7540.Peer-Reviewed Original ResearchNewly diagnosed myelomaProgression free survivalPhase 3 trialTreatment of newly diagnosed myelomaMedian progression free survivalRandomized phase 3 trialNewly diagnosed multiple myelomaLong-term follow-upProteasome inhibitorsBortezomib (VPlasma cell leukemiaLong-term resultsIntent to transplantR-maintenanceOS probabilityMedian followFree survivalInduction regimenCell leukemiaMedian ageSurvival outcomesMultiple myelomaInitial treatmentBaseline characteristicsFollow-up
2024
Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
Canadeo A, Giever E, Szabo A, Jin Y, Winer E, Badar T, Campos J, Lin C, Anderson C, Shallis R, Muradashvili T, Coltoff A, Guo Q, Patel A, Goldberg L, Abaza Y, Fariduddin M, Ayoub R, Foucar C, Nai N, Kota V, Dalgetty M, Gold M, Guduru M, Atallah E. Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium. Blood 2024, 144: 5174-5174. DOI: 10.1182/blood-2024-198914.Peer-Reviewed Original ResearchWhite blood cell countAcute promyelocytic leukemiaIncidence of relapseHigh-risk diseaseAll-Trans Retinoic AcidOverall survivalDifferentiation syndromeHigh riskArsenic trioxideInduction regimenTreatment regimensSupportive care strategiesCardiovascular comorbiditiesMedian white blood cell countData collection formDoses of gemtuzumab ozogamicinIncidence of CNS relapseIncidence of differentiation syndromeLow incidence of relapseOutcome of APL patientsSuspected acute promyelocytic leukemiaCumulative incidence of relapseDiagnosis of acute promyelocytic leukemiaLow-risk acute promyelocytic leukemiaMortality rate
2023
Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.Peer-Reviewed Original ResearchStandard-risk patientsHigh-risk patientsOverall response rateRisk patientsPFS benefitInduction therapyHR patientsInduction regimenMyeloma patientsNDMM patientsTransplant-eligible multiple myeloma patientsInternational Myeloma Working Group Uniform Response CriteriaHigh-risk MM patientsEffective induction regimenHigh-risk cytogeneticsCombination of lenalidomideHigh-risk diseaseMultiple myeloma patientsUniform response criteriaDepth of responseLong-term outcomesEvidence of benefitMaintenance therapyOS benefitClinical characteristics
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic value
2020
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, Parker T, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder J, Faber E, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar S. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. Journal Of Clinical Oncology 2020, 38: lba3-lba3. DOI: 10.1200/jco.2020.38.18_suppl.lba3.Peer-Reviewed Original ResearchProgression-free survivalPhase III trialsInitial therapyIII trialsHazard ratioMedian progression-free survivalRandomized phase 3 trialRandomized phase III trialNext-generation proteasome inhibitorsDexamethasone Versus BortezomibStandard initial therapyPhase 3 trialPhase II trialPlasma cell leukemiaISS stageLen-DexLens maintenanceNeuropathy ratesInduction regimenFree survivalII trialPFS eventsMedian ageMultiple myelomaRenal toxicity
2018
Phase II LAPACT trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
Hammel P, Lacy J, Portales F, Sobrero A, Pazo Cid R, Manzano Mozo J, Terrebonne E, Dowden S, Shiansong Li J, Ong T, Nydam T, Philip P. Phase II LAPACT trial of nab -paclitaxel ( nab -P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). Journal Of Clinical Oncology 2018, 36: 204-204. DOI: 10.1200/jco.2018.36.4_suppl.204.Peer-Reviewed Original ResearchProgression-free survivalDisease control rateOverall response rateTreatment failureAdverse eventsProgressive diseaseOverall survivalICS treatmentEastern Cooperative Oncology Group performance statusInvestigator's choiceGrade 3 peripheral neuropathyMedian progression-free survivalTreatment-emergent adverse eventsCycles of nabAdvanced pancreatic cancerKey secondary endpointMedian TTFTreatment-naive patientsPhase 2 trialUnacceptable adverse eventsPancreatic tumor burdenInduction therapyUnresectable LAPCInduction regimenNab-paclitaxel
2017
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Stahl M, Lu BY, Kim TK, Zeidan AM. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Targeted Oncology 2017, 12: 413-447. PMID: 28664386, DOI: 10.1007/s11523-017-0503-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaNovel therapiesMyeloid leukemiaHematopoietic stem cell transplantationImmune checkpoint inhibitorsStem cell transplantationStandard of careNovel therapeutic approachesKey clinical studiesForm of vaccinesBispecific monoclonal antibodyCheckpoint inhibitorsInduction regimenOverall survivalSupportive careYounger patientsAML therapyCell-based therapiesCell transplantationClinical trialsMetabolic therapyPro-apoptotic agentsClinical studiesTherapeutic approachesTemporal improvement
2016
Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic Advances In Hematology 2016, 8: 13-20. PMID: 28042455, PMCID: PMC5167078, DOI: 10.1177/2040620716676256.Peer-Reviewed Original ResearchProgression-free survivalNodular sclerosis Hodgkin lymphomaSyncytial variantOverall survivalHodgkin's lymphomaSV patientsComplete responseSV groupShorter progression-free survivalMedian overall survivalOutcomes of patientsPoor-risk groupLower CR rateInstitutional review board approvalKaplan-Meier methodSmall case seriesLog-rank testClassical HL patientsReview board approvalAdvanced diseaseInduction regimenAdult patientsClinical characteristicsHL patientsAggressive course
2015
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States
Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Clinical Infectious Diseases 2015, 62: 784-791. PMID: 26658053, PMCID: PMC4772845, DOI: 10.1093/cid/civ981.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careVirologic suppressionART costsBudget impactHuman immunodeficiency virus (HIV) treatmentART-naive patientsDTG/ABC/3TCVirologic suppression ratesSubsequent virologic failureCost-effectiveness ratioPerson/yearInitial regimenAntiretroviral therapyInduction regimenNaive patientsVirologic failureAntiretroviral agentsDual therapyHIV infectionTwo-drugDolutegravirVirus treatmentRegimenSurvival rate
2014
The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant
Chandraker A, Arscott R, Murphy G, Lian C, Bueno E, Marty F, Rennke H, Milford E, Tullius S, Pomahac B. The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant. American Journal Of Transplantation 2014, 14: 1446-1452. PMID: 24797454, DOI: 10.1111/ajt.12715.Peer-Reviewed Original ResearchConceptsAntibody-mediated rejectionPostoperative day 5Management of AMRDonor-specific antibody titersSubsequent antibody-mediated rejectionGrade III rejectionStandard induction regimenAnti-HLA antibodiesExtensive chemical burnsComposite tissue allotransplantationFull face transplantationMechanism of actionPreoperative crossmatchPresensitized recipientsSensitized recipientsDSA levelsInduction regimenC4d depositsPositive donorsBanff classificationAntibody titersCombination therapyPoor functionHistological signsClinical signs
2012
Rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) followed by consolidation high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT) for newly diagnosed primary CNS lymphoma (PCNSL).
Omuro A, Correa D, Moskowitz C, Matasar M, DeAngelis L, Kaley T, Gavrilovic I, Nolan C, Pentsova E, Grommes C, Abrey L, Sauter C. Rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) followed by consolidation high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT) for newly diagnosed primary CNS lymphoma (PCNSL). Journal Of Clinical Oncology 2012, 30: 2008-2008. DOI: 10.1200/jco.2012.30.15_suppl.2008.Peer-Reviewed Original ResearchAutologous stem cell transplantHigh-dose chemotherapyPrimary CNS lymphomaConsolidation high-dose chemotherapyITT populationR-MPVInduction chemotherapyInduction regimenPrimary endpointYear event-free survivalEffective induction regimenEvent-free survivalPhase II trialStem cell transplantImproved response ratesExcellent disease controlComprehensive neuropsychological evaluationHDC regimenHDC-ASCTMedian EFSYear EFSEarly complicationsMedian PFSCNS lymphomaII trial
1993
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, Herndon R, Lehrich JR, Hauser SL, Turel A, Fisher M, Birnbaum G, McArthur J, Butler R, Moore M, Sigsbee B, Safran A. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993, 43: 910-8. PMID: 8388090, DOI: 10.1212/wnl.43.5.910.Peer-Reviewed Original ResearchConceptsMajority of patientsInduction regimenTreatment failureTreatment groupsCyclophosphamide pulse therapyPatients 40 yearsPatients ages 41Progressive MS patientsPulse cyclophosphamide therapyPatients age 18Progressive multiple sclerosisNonbooster groupPulse therapyCyclophosphamide therapyProgressive MSMS patientsMultiple sclerosisDisease progressionSignificant benefitsAge 41Subsequent progressionPatientsInitial stabilizationAge 18Regimen
1992
Flow cytometric analysis of deoxyribonucleic acid in human granulosa cells as a function of chronological age and ovulation induction regimen
Seifer DB, Honig J, Penzias AS, Lavy G, Nadkarni PM, Jones EE, DeCherney AH, Flynn SD. Flow cytometric analysis of deoxyribonucleic acid in human granulosa cells as a function of chronological age and ovulation induction regimen. The Journal Of Clinical Endocrinology & Metabolism 1992, 75: 636-640. PMID: 1639962, DOI: 10.1210/jcem.75.2.1639962.Peer-Reviewed Original ResearchConceptsHuman menopausal gonadotropinOvulation induction regimenGreater proliferative indexInduction regimenLeuprolide acetateProliferative indexGranulosa cellsGroup IGroup IIGroup IIIAmpules of hMGFunction of ageFlow cytometryDay of hCGProspective cohort studyGroup of patientsHuman granulosa cellsChronological ageMenopausal gonadotropinCohort studyOvulation inductionSerum FSHSignificant independent influenceOutcome measuresWomen's ageFlow cytometric analysis of deoxyribonucleic acid in human granulosa cells as a function of chronological age and ovulation induction regimen
Seifer D. Flow cytometric analysis of deoxyribonucleic acid in human granulosa cells as a function of chronological age and ovulation induction regimen. The Journal Of Clinical Endocrinology & Metabolism 1992, 75: 636-640. DOI: 10.1210/jc.75.2.636.Peer-Reviewed Original Research
1988
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988, 38: 9-14. PMID: 2838768.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisChronic progressive multiple sclerosisMultiple sclerosisShorter disease durationMajority of patientsDosage of medicationCurrent treatment programsInduction regimenComplication rateDisease durationFrequent complicationLate complicationsYounger patientsPermanent remissionTreatment regimenInitial treatmentBooster injectionMaintenance treatmentMinor infectionsPatientsRemissionTreatment programRegimenComplicationsSingle treatment
1977
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood PlateletsClinical Trials as TopicCyclophosphamideDrug Therapy, CombinationFemaleHumansLeukocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRadiation DosageRadiation InjuriesRemission, SpontaneousTime FactorsVincristineConceptsHigher overall response rateCyclic combination chemotherapyOverall response rateCombination chemotherapyMedian followupResponse rateSimilar complete remission ratesRelapse-free survival rateComparison of chemotherapyMonths median followupComplete remission rateOverall median survivalDisease-free survivalTotal body irradiationNodular mixed lymphomaInduction regimenInduction therapyComplete remissionMedian survivalProspective trialRemission rateUntreated patientsMixed lymphomaMalignant lymphomaNodular lymphoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply